A practical framework for deciding how much weight to place on favorable or unfavorable predictions—and when confidence, applicability and decision consequence require experimental evidence.
Evaluate Your Prediction StrategyAn in silico ADMET prediction is most useful when its endpoint is precisely defined, the compound lies within the model's applicability domain, the training measurements are relevant and well curated, and the model has been tested on genuinely independent chemistry. A favorable prediction can lower the priority of an experimental test in early, reversible ranking decisions; an unfavorable prediction can flag a liability or help select compounds for confirmation. Neither result is a laboratory measurement. Confidence should therefore be judged separately from the direction of the prediction. A model can be confident and wrong for a novel scaffold, or uncertain while still correctly flagging a risky region of chemical space. The practical question is not whether "ADMET AI" is reliable in general. It is whether a particular model output is reliable enough for a particular compound, endpoint and decision. As decision consequence rises—from virtual triage to lead nomination—the required evidence should progress from model checks and consensus to endpoint-specific experiments, exposure-aware interpretation and, where relevant, in vivo or clinical evidence.
Examples include inhibitor/non-inhibitor, high/low permeability or alert/no alert. Review the decision threshold, class balance, sensitivity, specificity, precision and calibration. A probability near 0.5 carries a different meaning from one near a well-calibrated extreme.
Examples include logS, intrinsic clearance, fraction unbound or IC50. Interpret the prediction with units, transformation, experimental range, prediction error and interval. Error in log units can translate into a substantial fold difference.
Similarity scores, structural alerts and ensemble rankings often support prioritization rather than direct biological interpretation. Their meaning depends on how the score was derived and whether it maps to an experimentally defined endpoint.
Similarity, leverage, local density or distance-based criteria indicate whether the query is represented by the model's training experience.
Global dataset size matters less than coverage near the relevant scaffold, ionization pattern, lipophilicity range, stereochemistry and modality.
Correct structures, consistent units, assay metadata, replicate handling, censored values and duplicate resolution shape the learnable signal.
Performance must be reviewed for the specific endpoint, metric, validation split, class distribution and operating threshold used in the decision.
Different protocols, biological systems, concentrations and readouts can create endpoint labels that are nominally similar but experimentally distinct.
Confidence scores become decision-useful when observed error rates track predicted confidence and uncertainty increases for unfamiliar chemistry.
Endpoint biology and assay design set different ceilings on predictability. Physicochemical properties measured under defined conditions may support relatively direct structure–property learning. Cellular, organ-level and toxicity endpoints integrate multiple mechanisms and frequently contain greater biological and protocol variability. The validation question must therefore match the endpoint and intended use.
| Endpoint family | Typical output | Major sources of variability | Useful validation view | Practical follow-up |
|---|---|---|---|---|
| Solubility / lipophilicity / ionization | Continuous value or category at a stated pH | Solid form, pH, kinetic versus thermodynamic protocol, salts and aggregation | External error distribution by property range and chemical series | Measure under formulation- and route-relevant conditions |
| Permeability / absorption | Apparent permeability, absorption class or efflux risk | Cell line, transporter expression, recovery, pH gradient and solubility | Series-aware validation with threshold performance and recovery checks | Cell-based permeability/efflux assay with concentration context |
| Metabolic stability / clearance | Half-life, intrinsic clearance or stability class | Species, matrix, protein concentration, nonspecific binding and extrahepatic pathways | Separate validation by assay system, species and clearance range | Microsomal or hepatocyte stability; IVIVE when exposure translation is needed |
| CYP and transporter liabilities | Substrate/inhibitor probability, IC50/Ki estimate or alert | Isoform, probe substrate, incubation design, time dependence, metabolites and exposure | Per-isoform metrics, calibrated thresholds and external chemistry | Mechanistic in vitro testing followed by exposure-based interpretation |
| Toxicity endpoints | Alert, probability, potency estimate or multi-label profile | Cell type, dose, duration, species, mechanism, class imbalance and label aggregation | Endpoint-specific sensitivity, precision, calibration and scaffold/time split | Orthogonal assays selected around the predicted mechanism and expected exposure |
| PK parameters | Clearance, volume, bioavailability, half-life or exposure estimate | Coupled ADME processes, species, dose, formulation and route | Prospective or external compounds with parameter-wise and profile-level error | Combine measured inputs, IVIVE, animal PK or PBPK according to the question |
First determine whether the output is favorable or unfavorable. Then evaluate confidence from applicability domain, local support, model agreement, calibration and endpoint-specific validation. Finally, scale the action to the consequence and reversibility of the decision.
Key distinction: the direction of a prediction and confidence in that prediction are separate variables. Decision criticality determines how much independent evidence is required.
Chemical-space coverage should be assessed locally. A large training set can still provide little support around a particular scaffold. Random train/test splits often place close analogues on both sides of the split and can therefore overstate performance expected on future or structurally novel chemistry. Scaffold, cluster and time-based splits usually provide a more demanding view of generalization.
Duplicates, salts, mixtures, tautomer handling, stereochemistry and incorrect structures can create contradictory examples.
Units, transformations, limits of quantification, censored values, replicate variation and protocol differences affect the target.
Class imbalance, narrow chemistry, series dominance, missing metadata and selective publication influence apparent performance.
Data leakage, analogue leakage, metric selection and threshold tuning can make a model appear stronger than its prospective use.
Assay heterogeneity is particularly important when public data are aggregated. Two records labeled "solubility," "CYP3A4 inhibition" or "hepatotoxicity" may differ in protocol, biological system, concentration, time point and endpoint definition. Curation should preserve provenance and separate incompatible measurements instead of forcing them into one target. For classification, examine class prevalence and the cost of false negatives versus false positives. For regression, inspect absolute and fold error across the measured range rather than relying on correlation alone.
Prediction review is most useful when the endpoint, chemical series and downstream decision are defined together. The following existing services support complementary parts of that workflow.
Endpoint-specific computational screening, confidence review and compound prioritization.
Explore the service →Computational toxicity profiling and risk prioritization across relevant safety endpoints.
Explore the service →PK-oriented prediction and interpretation for exposure and development decisions.
Explore the service →Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk
